Companies › NGGT
1 active drug program in 1 registered trial: 1 Phase 1; Metabolic and endocrine; next expected readout Dec 2030.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| NGGT002 Adeno-associated viral vector with human phenylalanine hydroxylase gene | PAH | Phase 1 | Phenylketonurias | Dec 2030 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT06332807 | NGGT002 | Phase 1 | Phenylketonurias | Metabolic and endocrine | Dec 2030 |
BioMarin Pharmaceutical PTC Therapeutics Chongqing Peg-Bio Biopharm Agios Pharmaceuticals NGGT (Suzhou) Biotechnology
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.